Intestinal Lipid Mediators of Mucosal Repair: Mechanisms, Clinical Implications, and Therapeutic Advances

Abstract

Intestinal mucosal repair is a critical physiological process that determines the outcome of various gastrointestinal diseases. Lipid mediators, derived from dietary and endogenous sources, play a pivotal role in orchestrating mucosal healing through complex molecular mechanisms. This review synthesizes recent evidence on the roles of intestinal lipid mediators in mucosal repair, highlighting their pathophysiological significance, clinical implications, and potential as therapeutic targets. Understanding these mechanisms is essential for developing innovative strategies to enhance mucosal healing and improve patient outcomes in gastrointestinal disorders.

Introduction

The integrity of the intestinal mucosa is constantly challenged by mechanical, chemical, and microbial insults. Effective mucosal repair is essential to restore barrier function, limit inflammation, and maintain homeostasis. Lipid mediators including prostaglandins, leukotrienes, resolvins, and specialized pro-resolving mediators (SPMs) have emerged as central regulators of this reparative process. Recent scientific advances have elucidated the molecular pathways by which these lipid-derived signals modulate inflammation and tissue regeneration, offering promising avenues for clinical intervention in conditions such as inflammatory bowel disease (IBD), infectious enteritis, and ischemic injury.

Epidemiology / Disease Burden

Diseases marked by defective mucosal repair, such as IBD, celiac disease, and gastrointestinal infections, affect millions worldwide, imposing significant morbidity, healthcare costs, and mortality. The prevalence of IBD alone is rising globally, with estimates exceeding 6.8 million affected individuals. Complications from impaired mucosal healing, including strictures, fistulas, and increased risk of infection, underscore the urgent need for novel therapies targeting mucosal repair pathways.

Pathophysiology

Mucosal injury triggers a cascade of events involving epithelial restitution, proliferation, and differentiation. Lipid mediators are synthesized from membrane-derived fatty acids via cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 pathways. Prostaglandins (e.g., PGE2) promote epithelial migration and proliferation through EP receptor signaling, enhancing restitution. Leukotrienes and thromboxanes modulate inflammation and vascular responses. SPMs including resolvins, protectins, and maresins actively resolve inflammation and stimulate tissue regeneration. Dysregulation of these pathways leads to impaired healing and chronic inflammation.

Risk Factors

Risk factors for defective mucosal repair and altered lipid mediator profiles include genetic predispositions (e.g., variants in COX-2, LOX), chronic use of NSAIDs, dietary imbalances (deficiency in omega-3/omega-6 fatty acids), smoking, microbiome dysbiosis, and persistent inflammatory stimuli. Malnutrition and certain medications can also disrupt lipid mediator synthesis, undermining mucosal recovery.

Clinical Features

Clinically, impaired mucosal repair manifests as persistent abdominal pain, diarrhea, rectal bleeding, weight loss, and malabsorption. Endoscopic evaluation may reveal ulcerations, erosions, and compromised barrier function. In severe cases, patients are at increased risk of complications such as perforation, abscess formation, and sepsis. Laboratory markers often reflect ongoing inflammation and compromised barrier integrity.

Diagnosis

Diagnosis of disorders involving defective mucosal repair relies on a combination of clinical assessment, endoscopy, histopathology, and increasingly, biomarker profiling. Measurement of fecal calprotectin, serum inflammatory markers, and advanced lipidomic analyses can provide insights into the activity of lipid mediator pathways. Tissue biopsies allow for direct assessment of healing and mediator expression at the site of injury.

Treatment & Management

Current management strategies focus on controlling inflammation, promoting healing, and restoring mucosal integrity. Aminosalicylates, corticosteroids, and immunomodulators are mainstays in IBD. Nutritional support and avoidance of NSAIDs are crucial adjuncts. Emerging evidence supports the use of omega-3 fatty acid supplementation for their beneficial effects on lipid mediator production. Prostaglandin analogs, such as misoprostol, have demonstrated efficacy in specific contexts (e.g., NSAID-induced injury), but broad clinical use remains limited.

Recent Advances / Emerging Therapies

Recent advances in lipidomics and molecular biology have led to the identification of novel SPMs with potent pro-repair effects. Preclinical models demonstrate that administration of resolvins and protectins accelerates mucosal healing and attenuates inflammation. Gene-editing approaches targeting key enzymes in lipid mediator pathways are under investigation. Clinical trials are exploring the safety and efficacy of SPM analogs and dietary interventions to enhance endogenous lipid mediator production. Personalized medicine approaches, integrating genetic and lipidomic profiling, hold promise for optimizing repair-focused therapies.

Guideline Recommendations

International guidelines emphasize the importance of early recognition and management of mucosal injury, with a focus on minimizing further damage and supporting repair processes. While direct targeting of lipid mediators is not yet standard, recommendations include optimizing anti-inflammatory regimens, nutritional status, and minimizing exposure to agents that disrupt lipid synthesis. Ongoing research is expected to inform future guideline updates, particularly as new therapies move from bench to bedside.

Conclusion

Intestinal lipid mediators are central to the regulation of mucosal repair, bridging the gap between inflammation and tissue regeneration. Advances in understanding their mechanisms have opened new therapeutic possibilities for enhancing mucosal healing in gastrointestinal disorders. Continued translational research and clinical trials will be vital to harness the full potential of lipid mediators, ultimately improving patient outcomes in this challenging domain.